Stem definition | Drug id | CAS RN |
---|---|---|
2728 | 396-01-0 |
Dose | Unit | Route |
---|---|---|
0.10 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.03 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 13.15 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 51 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 13 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 63 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.42 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 4.30 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 10, 1964 | FDA | CONCORDIA PHARMS INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Gastrooesophageal reflux disease | 44.03 | 12.87 | 75 | 13219 | 76353 | 50515477 |
Myocardial infarction | 43.14 | 12.87 | 81 | 13213 | 88946 | 50502884 |
Oedema peripheral | 41.89 | 12.87 | 113 | 13181 | 157848 | 50433982 |
Off label use | 34.03 | 12.87 | 45 | 13249 | 474381 | 50117449 |
Crystal nephropathy | 32.55 | 12.87 | 11 | 13283 | 804 | 50591026 |
Blood potassium decreased | 32.26 | 12.87 | 44 | 13250 | 36901 | 50554929 |
Focal segmental glomerulosclerosis | 30.70 | 12.87 | 12 | 13282 | 1329 | 50590501 |
Coronary artery disease | 29.97 | 12.87 | 38 | 13256 | 29688 | 50562142 |
Cerebrovascular accident | 28.43 | 12.87 | 71 | 13223 | 94609 | 50497221 |
Drug intolerance | 22.46 | 12.87 | 15 | 13279 | 219089 | 50372741 |
Diabetic neuropathy | 22.05 | 12.87 | 13 | 13281 | 3578 | 50588252 |
Product use issue | 22.04 | 12.87 | 6 | 13288 | 149469 | 50442361 |
Exposure during pregnancy | 21.74 | 12.87 | 3 | 13291 | 121012 | 50470818 |
Product complaint | 20.89 | 12.87 | 20 | 13274 | 11446 | 50580384 |
Transient ischaemic attack | 20.40 | 12.87 | 33 | 13261 | 32177 | 50559653 |
Systemic lupus erythematosus | 20.07 | 12.87 | 6 | 13288 | 140616 | 50451214 |
Pneumonia aspiration | 19.95 | 12.87 | 32 | 13262 | 30972 | 50560858 |
Transient acantholytic dermatosis | 19.14 | 12.87 | 4 | 13290 | 43 | 50591787 |
Depression | 19.06 | 12.87 | 90 | 13204 | 165333 | 50426497 |
Deep vein thrombosis | 18.95 | 12.87 | 52 | 13242 | 73252 | 50518578 |
Pulmonary embolism | 18.68 | 12.87 | 64 | 13230 | 101640 | 50490190 |
Product use in unapproved indication | 18.34 | 12.87 | 4 | 13290 | 115815 | 50476015 |
Wound | 18.14 | 12.87 | 3 | 13291 | 105791 | 50486039 |
Hyponatraemia | 18.10 | 12.87 | 61 | 13233 | 96078 | 50495752 |
Feeling abnormal | 17.27 | 12.87 | 72 | 13222 | 125420 | 50466410 |
Blood pressure increased | 17.25 | 12.87 | 75 | 13219 | 133057 | 50458773 |
Injury | 17.17 | 12.87 | 39 | 13255 | 48886 | 50542944 |
Mitral valve incompetence | 17.08 | 12.87 | 22 | 13272 | 17449 | 50574381 |
Vitamin B6 deficiency | 17.02 | 12.87 | 4 | 13290 | 76 | 50591754 |
Hypokalaemia | 16.71 | 12.87 | 56 | 13238 | 87936 | 50503894 |
Glossodynia | 16.37 | 12.87 | 5 | 13289 | 115564 | 50476266 |
Cardiac failure congestive | 16.29 | 12.87 | 54 | 13240 | 84328 | 50507502 |
Asthenia | 16.28 | 12.87 | 141 | 13153 | 318901 | 50272929 |
Drug ineffective | 16.13 | 12.87 | 138 | 13156 | 819195 | 49772635 |
Dizziness | 16.10 | 12.87 | 150 | 13144 | 346219 | 50245611 |
Lacunar infarction | 15.94 | 12.87 | 10 | 13284 | 3077 | 50588753 |
Anxiety | 15.86 | 12.87 | 90 | 13204 | 177516 | 50414314 |
Blood triglycerides increased | 15.63 | 12.87 | 17 | 13277 | 11295 | 50580535 |
Hyperlipidaemia | 15.52 | 12.87 | 21 | 13273 | 17469 | 50574361 |
Fear | 15.30 | 12.87 | 19 | 13275 | 14530 | 50577300 |
Blood sodium decreased | 15.24 | 12.87 | 23 | 13271 | 21124 | 50570706 |
Osteoarthritis | 15.15 | 12.87 | 46 | 13248 | 68560 | 50523270 |
Lung neoplasm | 15.08 | 12.87 | 12 | 13282 | 5370 | 50586460 |
Emotional distress | 15.02 | 12.87 | 27 | 13267 | 28636 | 50563194 |
Angina unstable | 14.75 | 12.87 | 13 | 13281 | 6693 | 50585137 |
Tubulointerstitial nephritis | 14.63 | 12.87 | 19 | 13275 | 15192 | 50576638 |
Dehydration | 13.44 | 12.87 | 77 | 13217 | 152372 | 50439458 |
Coma | 13.38 | 12.87 | 39 | 13255 | 56840 | 50534990 |
Infusion related reaction | 13.25 | 12.87 | 15 | 13279 | 169542 | 50422288 |
Spinal stenosis | 13.15 | 12.87 | 17 | 13277 | 13533 | 50578297 |
Ventricular hypertrophy | 13.14 | 12.87 | 9 | 13285 | 3206 | 50588624 |
Carpal tunnel syndrome | 13.08 | 12.87 | 19 | 13275 | 16874 | 50574956 |
Renal failure | 13.00 | 12.87 | 59 | 13235 | 106574 | 50485256 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Coronary artery disease | 31.41 | 17.11 | 36 | 4436 | 44154 | 29525901 |
Lymphopenia | 29.98 | 17.11 | 21 | 4451 | 13512 | 29556543 |
Myocardial infarction | 29.91 | 17.11 | 57 | 4415 | 110239 | 29459816 |
Activated partial thromboplastin time prolonged | 24.45 | 17.11 | 15 | 4457 | 7727 | 29562328 |
Dizziness | 22.24 | 17.11 | 71 | 4401 | 189613 | 29380442 |
Bundle branch block left | 18.67 | 17.11 | 11 | 4461 | 5266 | 29564789 |
Emotional distress | 18.61 | 17.11 | 16 | 4456 | 13879 | 29556176 |
Injury | 17.89 | 17.11 | 18 | 4454 | 19028 | 29551027 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myocardial infarction | 65.53 | 13.67 | 120 | 13118 | 165701 | 64319793 |
Coronary artery disease | 60.22 | 13.67 | 68 | 13170 | 60365 | 64425129 |
Gastrooesophageal reflux disease | 57.74 | 13.67 | 78 | 13160 | 83065 | 64402429 |
Cerebrovascular accident | 38.14 | 13.67 | 86 | 13152 | 137497 | 64347997 |
Injury | 35.07 | 13.67 | 50 | 13188 | 55942 | 64429552 |
Emotional distress | 34.95 | 13.67 | 40 | 13198 | 35998 | 64449496 |
Off label use | 33.36 | 13.67 | 49 | 13189 | 632757 | 63852737 |
Crystal nephropathy | 30.47 | 13.67 | 11 | 13227 | 1254 | 64484240 |
Pulmonary embolism | 25.60 | 13.67 | 77 | 13161 | 146279 | 64339215 |
Transient ischaemic attack | 25.55 | 13.67 | 38 | 13200 | 44144 | 64441350 |
Depression | 25.36 | 13.67 | 89 | 13149 | 183202 | 64302292 |
Hyperlipidaemia | 24.85 | 13.67 | 27 | 13211 | 22949 | 64462545 |
Oedema peripheral | 24.81 | 13.67 | 97 | 13141 | 210220 | 64275274 |
Focal segmental glomerulosclerosis | 24.47 | 13.67 | 12 | 13226 | 2932 | 64482562 |
Fear | 24.11 | 13.67 | 25 | 13213 | 20146 | 64465348 |
Deep vein thrombosis | 24.01 | 13.67 | 61 | 13177 | 105121 | 64380373 |
Anxiety | 22.73 | 13.67 | 92 | 13146 | 202557 | 64282937 |
Dizziness | 22.43 | 13.67 | 158 | 13080 | 430005 | 64055489 |
Product complaint | 22.36 | 13.67 | 19 | 13219 | 11935 | 64473559 |
Pyrexia | 21.69 | 13.67 | 52 | 13186 | 558592 | 63926902 |
Hyponatraemia | 21.35 | 13.67 | 73 | 13165 | 148266 | 64337228 |
Blood potassium decreased | 20.90 | 13.67 | 33 | 13205 | 40366 | 64445128 |
Mitral valve incompetence | 20.90 | 13.67 | 26 | 13212 | 25512 | 64459982 |
Cardiac failure congestive | 20.34 | 13.67 | 66 | 13172 | 130514 | 64354980 |
Ventricular hypertrophy | 20.22 | 13.67 | 14 | 13224 | 6502 | 64478992 |
Diabetic neuropathy | 19.69 | 13.67 | 13 | 13225 | 5588 | 64479906 |
Carpal tunnel syndrome | 19.61 | 13.67 | 20 | 13218 | 15808 | 64469686 |
Chest pain | 18.20 | 13.67 | 96 | 13142 | 235884 | 64249610 |
Myocardial ischaemia | 17.96 | 13.67 | 23 | 13215 | 23228 | 64462266 |
Transient acantholytic dermatosis | 17.32 | 13.67 | 4 | 13234 | 91 | 64485403 |
Asthenia | 17.18 | 13.67 | 148 | 13090 | 427896 | 64057598 |
Hypertension | 17.02 | 13.67 | 101 | 13137 | 259160 | 64226334 |
Renal failure | 16.92 | 13.67 | 78 | 13160 | 181610 | 64303884 |
Product use issue | 15.28 | 13.67 | 6 | 13232 | 151709 | 64333785 |
Feeling abnormal | 15.24 | 13.67 | 61 | 13177 | 133541 | 64351953 |
Blood sodium decreased | 15.13 | 13.67 | 24 | 13214 | 29458 | 64456036 |
Febrile neutropenia | 15.06 | 13.67 | 10 | 13228 | 187647 | 64297847 |
Renal injury | 14.74 | 13.67 | 17 | 13221 | 15412 | 64470082 |
Arteriosclerosis | 14.35 | 13.67 | 17 | 13221 | 15860 | 64469634 |
Hiatus hernia | 14.26 | 13.67 | 19 | 13219 | 19938 | 64465556 |
Enterocele | 14.11 | 13.67 | 3 | 13235 | 46 | 64485448 |
None
Source | Code | Description |
---|---|---|
ATC | C03DB02 | CARDIOVASCULAR SYSTEM DIURETICS ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS Other potassium-sparing agents |
FDA PE | N0000008859 | Decreased Renal K+ Excretion |
FDA PE | N0000175359 | Increased Diuresis |
FDA EPC | N0000175418 | Potassium-sparing Diuretic |
CHEBI has role | CHEBI:35498 | diuretics |
CHEBI has role | CHEBI:38633 | sodium channel blockers |
MeSH PA | D004232 | Diuretics |
MeSH PA | D062686 | Epithelial Sodium Channel Blockers |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D045283 | Natriuretic Agents |
MeSH PA | D026941 | Sodium Channel Blockers |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Edema | indication | 267038008 | |
Pulmonary Edema due to Chronic Heart Failure | indication | ||
Peripheral Edema due to Chronic Heart Failure | indication | ||
Hypokalemia | off-label use | 43339004 | |
Anuria | contraindication | 2472002 | DOID:2983 |
Hypercholesterolemia | contraindication | 13644009 | |
Hyperkalemia | contraindication | 14140009 | |
Secondary angle-closure glaucoma | contraindication | 21571006 | |
Hypovolemia | contraindication | 28560003 | |
Dehydration | contraindication | 34095006 | |
Hyperuricemia | contraindication | 35885006 | DOID:1920 |
Diabetes mellitus type 2 | contraindication | 44054006 | DOID:9352 |
Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
Acidosis | contraindication | 51387008 | |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Sympathectomy | contraindication | 57071006 | |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
Hypochloremic alkalosis | contraindication | 70134007 | |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Megaloblastic anemia due to folate deficiency | contraindication | 85649008 | DOID:14026 |
Hyponatremia | contraindication | 89627008 | |
Gout | contraindication | 90560007 | DOID:13189 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Kidney stone | contraindication | 95570007 | |
Hypomagnesemia | contraindication | 190855004 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Neonatal hyperbilirubinemia | contraindication | 281610001 | |
Pregnancy, function | contraindication | 289908002 | |
Azotemia | contraindication | 445009001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.22 | Basic |
pKa2 | 5.5 | Basic |
pKa3 | 2.21 | Basic |
pKa4 | 0.54 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Amiloride-sensitive sodium channel, ENaC | Ion channel | BLOCKER | IC50 | 5.30 | IUPHAR | CHEMBL | |||
Caspase-1 | Enzyme | IC50 | 5.44 | DRUG MATRIX | |||||
Solute carrier family 12 member 1 | Transporter | WOMBAT-PK | |||||||
Cytochrome P450 2D6 | Enzyme | IC50 | 5 | DRUG MATRIX | |||||
Cathepsin G | Enzyme | IC50 | 5.13 | DRUG MATRIX | |||||
Pteridine reductase 1 | Enzyme | Ki | 5.47 | CHEMBL |
ID | Source |
---|---|
4017902 | VUID |
N0000146253 | NUI |
D00386 | KEGG_DRUG |
4017902 | VANDF |
C0040869 | UMLSCUI |
CHEBI:9671 | CHEBI |
DX2 | PDB_CHEM_ID |
CHEMBL585 | ChEMBL_ID |
DB00384 | DRUGBANK_ID |
D014223 | MESH_DESCRIPTOR_UI |
5546 | PUBCHEM_CID |
4329 | IUPHAR_LIGAND_ID |
1266 | INN_ID |
WS821Z52LQ | UNII |
10763 | RXNORM |
5617 | MMSL |
80875 | MMSL |
d00396 | MMSL |
002315 | NDDF |
12512008 | SNOMEDCT_US |
387053007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
MAXZIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-0460 | TABLET | 75 mg | ORAL | NDA | 20 sections |
MAXZIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-0460 | TABLET | 75 mg | ORAL | NDA | 20 sections |
MAXZIDE-25 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-0464 | TABLET | 37.50 mg | ORAL | NDA | 20 sections |
MAXZIDE-25 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-0464 | TABLET | 37.50 mg | ORAL | NDA | 20 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-1352 | TABLET | 37.50 mg | ORAL | NDA | 23 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-1352 | TABLET | 37.50 mg | ORAL | NDA | 23 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-1355 | TABLET | 75 mg | ORAL | NDA | 23 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-1355 | TABLET | 75 mg | ORAL | NDA | 23 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-2537 | CAPSULE | 37.50 mg | ORAL | ANDA | 21 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0527-1632 | CAPSULE | 37.50 mg | ORAL | ANDA | 20 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0591-0348 | TABLET | 75 mg | ORAL | ANDA | 19 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0591-0348 | TABLET | 75 mg | ORAL | ANDA | 19 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0591-0424 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0591-0424 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0615-1333 | CAPSULE | 37.50 mg | ORAL | ANDA | 23 sections |
Triamterene hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0615-3583 | TABLET | 37.50 mg | ORAL | ANDA | 23 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-2074 | CAPSULE | 37.50 mg | ORAL | ANDA | 23 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-2715 | CAPSULE | 50 mg | ORAL | ANDA | 23 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10135-581 | CAPSULE | 37.50 mg | ORAL | ANDA | 20 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-049 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-076 | TABLET | 37.50 mg | ORAL | NDA | 22 sections |
Triamterene hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-080 | TABLET | 75 mg | ORAL | ANDA | 23 sections |
Triamterene hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-536 | TABLET | 37.50 mg | ORAL | ANDA | 23 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-537 | TABLET | 75 mg | ORAL | ANDA | 19 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16590-338 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
Triamterene hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-496 | TABLET | 37.50 mg | ORAL | ANDA | 21 sections |
Triamterene hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-497 | TABLET | 75 mg | ORAL | ANDA | 21 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-839 | CAPSULE | 37.50 mg | ORAL | ANDA | 23 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 33261-365 | TABLET | 75 mg | ORAL | ANDA | 19 sections |
Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 33261-952 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |